Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Aldosterone Synthase Inhibitors
Author(s): Shubh K Patel , Hwee Teoh , Ahreni Saunthar , et al Added: 6 months ago

Cardiovascular Renal Metabolic
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 1 year ago

Heart Failure
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 7 months ago

Heart Failure
ACC 24 Late-Breaker Discussion: The ARISE-HF Trial
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more

Heart Failure

Prevention & Chronic Conditions
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at American College of Cardiology Congress
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes… View more

Heart Failure

Cardiovascular Renal Metabolic
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
Author(s): Javed Butler , Dinesh Khullar , John JV McMurray , et al Added: 3 months ago
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He… View more

Prevention & Chronic Conditions

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 4 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
The Aldosterone Story: New Chapters
Author(s): Vijay Chopra Added: 7 months ago

Heart Failure
Early SGLT2i/MRA Use Benefits Suspected HF Patients
Added: 1 week ago Source:  Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes… View more

Intervention

Heart Failure
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Added: 6 months ago Source:  Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac… View more

Guidelines & Statements

Heart Failure